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It has been claimed that efficacy estimates based on the Hamilton Depression Rating-Scale
(HDRS) underestimate antidepressants true treatment effects due to the instrument’s poor
psychometric properties. The aim of this study is to compare efficacy estimates based on
the HDRS with the gold standard procedure, the Montgomery-Asberg Depression Rating-
Scale (MADRS).
Methods and findings
We conducted a meta-analysis based on the comprehensive dataset of acute antidepres-
sant trials provided by Cipriani et al. We included all placebo-controlled trials that reported
continuous outcomes based on either the HDRS 17-item version or the MADRS. We com-
puted standardised mean difference effect size estimates and raw score drug-placebo dif-
ferences to evaluate thresholds for clinician-rated minimal improvements (clinical
significance). We selected 109 trials (n = 32,399) that assessed the HDRS-17 and 28 trials
(n = 11,705) that assessed the MADRS. The summary estimate (effect size) for the HDRS-
17 was 0.27 (0.23 to 0.30) compared to 0.30 (0.22 to 0.38) for the MADRS. The effect size
difference between HDRS-17 and MADRS was thus only 0.03 and not statistically signifi-
cant according to both subgroup analysis (p = 0.47) and meta-regression (p = 0.44). Drug-
placebo raw score difference was 2.07 (1.76 to 2.37) points on the HDRS-17 (threshold for
minimal improvement: 7 points according to clinician-rating and 4 points according to
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patient-rating) and 2.99 (2.24 to 3.74) points on the MADRS (threshold for minimal improve-
ment: 8 points according to clinician-rating and 5 points according to patient-rating).
Conclusions
Overall there was no meaningful difference between the HDRS-17 and the MADRS. These
findings suggest that previous meta-analyses that were mostly based on the HDRS did not
underestimate the drugs’ true treatment effect as assessed with MADRS, the preferred out-
come rating scale. Moreover, the drug-placebo differences in raw scores suggest that treat-
ment effects are indeed marginally small and with questionable importance for the average
patient.
Introduction
The debate whether antidepressants are an effective treatment for depression is ongoing and
unresolved [1±5]. Although meta-analyses unequivocally produce statistically significant drug-
placebo differences in acute treatment trials [6±8], various researchers showed that these dif-
ferences are so small that their practical relevance is questionable [9±12]. A common reply to
these critics is that the most common outcome measure in depression trials, the Hamilton
Depression Rating Scale (HDRS), has poor validity, is not unidimensional, and is not sensitive
to symptom change because it contains items that presumably capture adverse effects of anti-
depressants rather than core depression symptoms [13±15]. According to this view, the wide-
spread application of the HDRS has resulted in a significant underestimation of antidepres-
sants' true treatment effects.
An alternative approach to examine the efficacy of antidepressants would be to base effect
size estimates on an outcome that is widely accepted as a reliable and valid measure of depres-
sion. One such outcome is the Montgomery-Asberg Depression-Rating Scale (MADRS),
which was constructed to be particularly sensitive to change and to treatment effects on core
depression symptoms [16]. Independent evaluations have confirmed that the MADRS is psy-
chometrically superior to the HDRS, that it is unidimensional, and that it should be the pre-
ferred outcome measure [17]. In accordance, the MADRS is considered the ªgold standard
clinician rating scale for depressionº [18].
The aim of this meta-analysis was thus to re-evaluate the data from short-term antidepres-
sant trials for adults with major depression collected by Cipriani et al. [6] by focusing on differ-
ences in effect size estimates for MADRS and HDRS. This comparison will empirically test the
claim that the predominant use of HDRS has resulted in an underestimation of antidepres-
sants' true treatment effects. If this assumption was true, then effect size estimates for the
MADRS should be substantially larger than estimates based on the HDRS. Given that the
interpretation of effect sizes is not straightforward (e.g. does an effect size of 0.3 represent a
practically relevant effect [9]?), we will further examine drug-placebo differences in raw scores
for both rating scales to evaluate the clinical significance of the drugs' average treatment effect.
If antidepressants provide clinically significant treatment effects on core depression symptoms,
then the drug-placebo difference in MADRS raw scores should exceed the threshold of a pre-
defined minimal important difference.
Methods
Since this a post-hoc analysis of a freely available dataset, we did not write a study protocol and
did not pre-register the planned analysis. That is, we did not conduct our own literature
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search, but relied on the work by Cipriani et al. [6]. Except for this omission, the study was
conducted and reported according to the PRISMA statement [19] and used established proce-
dures detailed in the Cochrane handbook [20].
Data source, study selection and outcomes
Our analysis was based on short-term, mostly 8-week clinical trials of antidepressants for
adults with unipolar major depression, reported in a recent systematic review by Cipriani et al.
[6]. The authors of this comprehensive study made the data available in a public repository
(https://data.mendeley.com/datasets/83rthbp8ys/2). This is the largest database of new-genera-
tion antidepressants for the acute treatment of major depression compiled thus far. The com-
prehensive literature search conducted by Cipriani et al. [6] yielded 522 trials (with 21
individual antidepressants), of which we extracted 253 trials owing to the following inclusion
criteria: first, they included a placebo-arm and, second, they also reported any outcome mea-
sure. However, various trials reported only response rates or used continuous outcome scores
other than ratings based on either HDRS-17 or MADRS. Therefore, of the 253 eligible trials,
we selected 109 (43%) that reported continuous outcomes based on the HDRS-17 and 28
(11%) based on the MADRS. The study flowchart is shown in Fig 1.
When trials had multiple treatment arms with different doses of antidepressants, these
arms were aggregated. This is an appropriate procedure, as low-to-medium doses achieve the
highest efficacy [21]. When trials compared different antidepressants, the data of these arms
were aggregated to have only one estimate for the overall analysis of the active drug relative to
placebo. The selected trials either reported pre-post differences (n = 169, 67%) or drug-placebo
differences at the end of treatment (n = 84, 33%). Since results for both outcomes were similar,
we did not report the analysis separately, as in previous publications with the same dataset [6,
11]. In addition to HDRS-17 and MADRS scores we also extracted year of publication, drop-
out-rate, sample size, and publication status (published vs. unpublished) from the database.
We did not conduct a formal risk of bias assessment, as this was extensively studied by Mun-
kholm et al. [11] in a previous analysis of this dataset.
Statistical analysis
We calculated the standardised mean differences for each trial and aggregated them by means
of a random effect meta-analysis based on the inverse variance method according to the proce-
dure suggested by Munkholm et al. [11] using the metafor package in R (version 3.4.3). We
ran a similar analysis using the raw score mean-differences to evaluate the clinical significance
of the summary estimates. For the analysis of individual antidepressants, only comparisons
with at least 3 trials using either the HDRS-17 or the MADRS were selected.
We used subgroup analysis and meta-regression to test for differences between the HDRS
and MADRS. Effect size estimates with corresponding 95% confidence intervals (CI) were
based on Hedges' g standardised mean difference method and the variability of effect sizes due
to heterogeneity was calculated as I2. Test statistics and confidence intervals were adjusted
according to the procedure by Hartung and Knapp, as recommended in the Cochrane hand-
book [20].
Classifying effect sizes as small or large based on arbitrary thresholds is not recommended
[22]. We therefore proposed that a more stringent approach to the evaluation of antidepressant
efficacy would be to put the drug-placebo difference in raw scores into context and to compare
them to empirically derived cut-off scores for clinical significance [9]. As demonstrated by
Leucht and colleagues, for a clinician to detect a minimal improvement at least 7 points are
required on the HDRS-17 [23] and about 8 points on the MADRS [24]. Moreover, with respect
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to the minimal important difference in patient-oriented outcomes (mostly quality of life), Bar-
rett et al. [25] detail that across various health problems, scores of about 7±9% of the maximum
scale score are necessary. With respect to the HDRS-17 (maximum score 52), the minimal
important difference would thus be about 4 points, while for the MADRS (maximum score
60), it would be about 5 points. If the upper bound of the confidence interval for the effect size
estimate is smaller than those thresholds, we consider that antidepressants' average treatment
effects are clinically not significant.
A sensitivity analysis included a meta-regression across all antidepressants and controlled
for potential confounders that differed between trials using the HDRS-17 and the MADRS.
These covariates included year of publication, drop-out-rate, sample size, and publication sta-
tus. We also cross-validated our findings with the standard methods for continuous outcomes
Fig 1. PRISMA study flowchart. Literature search and study selection conducted by Cipriani et al. [6] is depicted in grey, our own further study selection for this
particular analysis is depicted in black. RCTs: randomized controlled trials; HDRS-17: Hamilton Depression Rating Scale 17-item version, MADRS: Montgomery-
Asberg Depression Rating Scale.
https://doi.org/10.1371/journal.pone.0229381.g001
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proposed in the Cochrane handbook, the DerSimonian-Laird random-effects meta-analysis
and the inverse-variance fixed-effects method [20].
Results
Differences between HDRS and MADRS
For the overall analysis across different antidepressants, there were 137 trials/comparisons. A
full list of included studies is provided in the online supplement (S1 File) and for a description
of these studies see Cipriani et al. [6]. For the HDRS-17, the trials included a total of 32,399
patients, of which 19,796 received the active drug and 12,603 received placebo. For the
MADRS, a total of 11,705 patients were included; 7477 received active drug and 4228 received
placebo. As detailed by Munkholm et al. [11], most studies were rated at high or unclear risk
of bias with respect to allocation concealment and blinding of participants.
Aggregated across all drugs, the summary effects size (ES) for the HDRS-17 and the
MADRS were almost identical (ES = 0.27, CI = 0.23±0.30 vs. ES = 0.30, CI = 0.22±0.38), and
the difference was statistically not significant based on both subgroup analysis (Q = 0.53,
df = 1, p = 0.47) and meta-regression (b = -0.03, SE = 0.04, p = 0.44). Observed variability
across studies, which could indicate between-study heterogeneity, was low for the HAMD-17
(I2 = 45%) and moderate for the MADRS (I2 = 74%). The forest plot for the meta-analysis
across all drugs is shown in the online supplement (S1 File).
Analysis of individual drugs (k3 for both HDRS-17 and MADRS) was possible for bupro-
pion (k = 9), duloxetine (k = 17), escitalopram (k = 12), paroxetine (k = 21), venlafaxine
(k = 7), and vilazodone (k = 7). The results for the individual drugs are shown in Fig 2.
Although some effect size estimates differed between HDRS-17 and MADRS, confidence
intervals overlapped for all individual drugs. In the meta-regression analysis, the differences
achieved statistical significance for venlafaxine (b = -0.15, SE = 0.05, p = 0.02) and vilazodone
(b = -0.32, SE = 0.08, p = 0.005), but not for paroxetine (b = 0.01, SE = 0.08, p = 0.92), escitalo-
pram (b = -0.13, SE = 0.08, p = 0.12), duloxetine (b = -0.17, SE = 0.12, p = 0.20), and bupropion
(b = 04, SE = 0.09, p = 0.70). After correction for multiple testing (α = 0.008), the effect size
comparison between HDRS-17 and MADRS remained statistically significant only for vilazo-
done. The statistical tests based on subgroup analysis were nearly identical to the results of the
meta-regression and thus are not reported here. Forest plots for all individual drugs are shown
in the online supplement (S1 File).
SMD (95% CI): standardized mean difference based on Hedges' g and corresponding 95%
confidence interval, I2: heterogeneity index, p: p-value of the meta-regression analysis with the
instrument (HDRS-17 vs. MADRS) as predictor variable, k: number of trials, N: number of
participants (antidepressant plus placebo arm).
Clinical significance of treatment effects
As detailed in the methods section, the pre-defined threshold for a minimal improvement
according to clinician evaluation is 7 points on the HDRS and 8 points on the MADRS. Corre-
sponding cut-offs for a minimal important difference according to patient ratings are about 4
points for the HDRS-17 and 5 points for the MADRS. In the present meta-analysis, the drug-
placebo difference in raw scores was 2.07 (CI = 1.76±2.37) for the HDRS-17 (possible range
0±52 points) and 2.99 (CI = 2.24±3.74) for the MADRS (possible range 0±60 points) (S1 File).
Drug-placebo differences, for both HDRS-17 and MADRS, were thus clinically not significant.
The drug-placebo difference of 2.07 points on the HDRS-17 corresponds to 4% of the maxi-
mum scale score (52 points), whereas the difference of 2.99 points on the MADRS corresponds
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to 5% of the maximum scale score (60 points). These almost identical figures again demon-
strate that the drug effects assessed with HDRS-17 and MADRS do not differ meaningfully.
Sensitivity analysis
In univariate meta-regression analysis, trials using the HDRS-17 and the MADRS differed by
year of publication, dropout rate, and sample size, but not by publication status. In a multivari-
able meta-regression analysis that included all significant confounding variables as additional
predictor variables, the overall effect of the instrument (HDRS-17 compared to MADRS) was
statistically not significant and very small (B = -0.07, SE = 0.04, p = 0.06). The results were
almost identical when different meta-analytic methods were used. The inverse-variance fixed-
effects model produced estimates of ES = 0.25 (0.23±0.28) and ES = 0.30 (0.27±0.34) for
Fig 2. Meta-analytic results across all antidepressants and for individual antidepressants with sufficient number of trials (k3).
Horizontal lines denote the 95% confidence intervals of the point estimates. Meta-analytic results for trials using the HDRS-17 and the
MADRS are depicted in grey and black, respectively. The vertical dashed line indicates the overall result (SMD = 0.29) from the
Cipriani et al. [6] dataset as reported by Munkholm et al. [11].
https://doi.org/10.1371/journal.pone.0229381.g002
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HDRS-17 and MADRS, whereas based on the DerSimonian-Laird random-effects model the
estimates were ES = 0.26 (0.23±0.29) and ES = 0.30 (0.22±0.38).
Discussion
Principal findings
Our meta-analysis found a mean effect size of 0.30 (0.22±0.38) for the MADRS as compared to
0.27 (0.23±0.30) for the HAMD-17. That is, the effect sizes for both rating scales are compara-
ble when averaged over all drugs. Although the MADRS is considered the gold standard [18]
and the preferred depression rating scale due to its good psychometric properties [17], it does,
overall, not produce higher effect size estimates than the HDRS-17, which is considered ªpsy-
chometrically and conceptually flawedº [26]. Therefore, contrary to prominent claims, there is
no compelling evidence to assume that the efficacy of new-generation antidepressants is
underestimated due to the wide-spread application of the ªunresponsiveº full HDRS scale [14,
15, 27]. Moreover, with an estimated 2.07 drug-placebo difference in raw scores for the
HDRS-17 (4% of the maximum scale score) and a 2.99 difference for the MADRS (5% of the
maximum scale score), the drugs' treatment effect falls well below the empirically-derived
thresholds that both clinicians and patients would consider a minimal improvement [23±25].
Across various health problems, scores of about 7±9% of the maximum scale score are neces-
sary for patients to notice a minimal important difference [25], whereas for a clinician to detect
a minimal improvement at least 7 points are required on the HDRS-17 [23] and about 8 points
on the MADRS [24].
We cannot preclude with certainty that there is no difference between HDRS-17 and
MADRS for all individual drugs. After correction for multiple testing, for vilazodone the effect
size based on MADRS was statistically significantly larger than the effect size produced by the
HDRS-17. However, it is important to note that vilazodone's HDRS-17 effect size (ES = 0.09)
was considerably lower than the summary estimate for all drugs (ES = 0.27), whereas vilazo-
done's MADRS effect size (ES = 0.41) was above the average for all drugs (ES = 0.30). This is a
peculiar inconsistency, because if vilazodone was truly more efficacious than other drugs, this
should show in an above-average score for both HDRS-17 and MADRS, but not in a very low
HDRS-17 score and in a high MADRS score. This inconsistency might be explained by the low
proportion of published vilazodone trials using the HDRS-17 (2 of 6; 33%), whereas all three
trials using the MADRS were published (100%). It is known that the trials published in the sci-
entific literature exaggerate efficacy estimates [28, 29]. The significant effect size difference
between HDRS-17 and MADRS for vilazodone should thus be interpreted with caution, as this
is likely a methodological artefact.
Previous research tried to minimise biases assumed to underlie the full HDRS scale by
focusing on selected items. For instance, Bech developed a HDRS subscale that contains only
core depression symptoms [30]. In a recent review he reported various trials where this sub-
scale produced higher effect size estimates than the full HDRS scale [27], but these findings
appear to be systematically biased due to selective reporting. Indeed, with an unweighted
mean of 0.44 the summary effect size for the Bech-subscale reported by Bech [27] is consider-
ably larger than in the comprehensive meta-analysis by Hieronymus et al. [15], where it was
estimated with 0.35.
Hieronymus et al. [15] chose an even more reductionistic approach. They focused exclu-
sively on a single item of the HDRSÐthe mood itemÐand reported higher effect sizes for the
mood item compared to the total score (ES: 0.40 vs. 0.27). However, focusing on the mood
item of the HDRS has major limitations. Contrary to the MADRS and the Bech-subscale, the
psychometric properties of the mood item as a stand-alone outcome measure have never been
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validated. Moreover, simply because a specific outcome is more responsive to antidepressant
treatment effects does not imply that it is a valid measure of depression [31]. It is not clear
whether the mood item adequately captures the multifaceted construct of depression, as other
relevant core depression symptoms such as suicidality, fatigue, feelings of guilt or loss of inter-
est are ignored. This is particularly relevant, given that patients rate depressed mood as less
important than for instance fatigue or loss of interest [32].
Limitations
This study is not without limitations. First, it is important to note that the MADRS was applied
in relatively few trials and comparisons between MADRS and HDRS-17 for individual drugs
are thus limited to bupropion, duloxetine, escitalopram, paroxetine, venlafaxine, and vilazo-
done. However, it is unlikely that this restriction has introduced systematic bias. Gartlehner
et al. [33] conclude that differences in efficacy estimates between new-generation antidepres-
sants are not practically relevant, while Cipriani et al. [6] estimate the efficacy of these particu-
lar drugs as average (bupropion, duloxetine, vilazodone) or even above average (escitalopram,
paroxetine, venlafaxine). Second, confidence intervals for some individual drugs are rather
wide. Therefore, it cannot be ruled out that for some drugs the true effect might be consider-
ably larger or smaller. However, given that differences in effect size estimates between individ-
ual drugs are very small [6, 33], we suggest that the summary estimate of 0.30 for the MADRS
accurately reflects the true average treatment effect of all new-generation antidepressants.
Third, it should be kept in mind that most trials included in this meta-analysis were sponsored
by the drug manufacturers and that efficacy estimates based on industry-sponsored trials are
likely overestimations due to various systematic method biases [9, 11, 34]. Fourth, most studies
were rated at high or unclear risk of bias with respect to allocation concealment and blinding
of participants [11], which also results in exaggerated effect size estimates in trials of subjective
outcomes such as the HDRS or MADRS [35, 36]. We thus must remain mindful that the
reported effect sizes represent upper-bound estimates.
Conclusions
The effect size estimates reported in recent meta-analyses of antidepressants that were mostly
based on the highly criticised HDRS-17 do not appear to underestimate the drugs treatment
effects. When efficacy estimates are based on the MADRS, the preferred rating scale for
depression that is particularly sensitive to change in core depression symptoms, the effect size
estimates do not differ meaningfully. Moreover, we found that the average drug-placebo differ-
ence in raw scores for both the HDRS-17 and MADRS fall short of the cut-offs for a minimally
important improvement. Prominent claims that the HDRS has significantly underestimated
antidepressants' true efficacy are thus not based on convincing evidence. A more plausible
explanation would be that the efficacy of antidepressants is indeed poor and of questionable
importance to the average patient.
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